Magnetically responsive nanoparticle therapeutic constructs and methods of making and using

• US 8,651,113 B2
• Filed: 07/17/2009
• Issued: 02/18/2014
• Est. Priority Date: 06/18/2003
• Status: Active Grant

• Current Assignee: Swr&D Inc., Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Swr&D Inc.
• Inventors: Seeney, Charles E., Klostergaard, Jim, Yuill, William A., Gibson, Donald D.
• Primary Examiner(s): Marmor, II, Charles A
• Assistant Examiner(s): KUHLMAN, CATHERINE BURK
• Application Number:
  US12/505,111
• Publication Number:
  US 20110130616A1
• Time in Patent Office: 1,677 Days
• Field of Search: 128897-899, 600 9- 15
• US Class Current: 128/899
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1676 having a drug-free core with discrete complete coating layer containing drug adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921
• CPC Class Codes: A61K 9/5094 Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
• CPC Class Codes: A61N 2/12 using variable magnetic fields obtained by mechanical movement

Abstract

Magnetically responsive therapeutic carriers comprise nanoparticles including single-domain nanoparticles comprising magnetite and having an average particle size ranging between 1 and 50 nanometers, clusters of the single-domain nanoparticles, the clusters having an average cluster size ranging between 5 and 1000 nanometers, and mixtures of the two. The single-domain nanoparticles are encapsulated with a silica coating. A silane coupling agent is bonded to the silica coating and has a specific pendant functional group capable of selectively binding with the therapeutic. Preferably, the bond between the specific pendant functional group and the therapeutic is a covalent bond. The movement of magnetically responsive nanoparticle therapeutic constructs, with concentration and extravasation/endocytosis at a target site, such as cancerous tumors, uses a controllable magnetic field generator adapted to move the therapeutic constructs in three dimensions, and is enhanced using a repetitively-varying magnetic field. A method for treating cancer comprises administering and magnetically guiding a therapeutic construct comprising paclitaxel.

Claims

1. A method for delivering a therapeutic to target cells within a body, the method comprising the following steps:

preparing magnetically responsive therapeutic constructs comprising;

magnetically responsive carrier nanoparticles selected from the group consisting of;

(a) single-domain nanoparticles comprising magnetite and having an average particle size ranging between 1 and 50 nanometers, (b) clusters of single-domain nanoparticles comprising magnetite, the particles having an average particle size ranging between 1 and 50 nanometers, the clusters having an average cluster ranging between 5 and 1000 nanometers, and mixtures of (a) and (b);

a silica coating encapsulating the single-domain nanoparticles;

a silane coupling agent bonded to the silica coating and having a specific pendant functional group comprises a carboxyl group capable of selectively binding with the therapeutic; and

the therapeutic chemically bonded to the silane coupling agent;

wherein the silane coupling agent comprises an alkoxysilylpropyl-O-polyethylene oxide urethane containing monomer units of polyethylene glycol (PEG) terminating in an alcohol function which has been oxidized to a carboxyl group;

introducing the magnetically responsive therapeutic constructs into the body; and

moving the therapeutic constructs to the target cell using a controllable magnetic field generator adapted to move the carrier nanoparticles in three dimensions.

2. The method of claim 1 wherein the magnetically responsive nanoparticles comprise superparamagnetic nanoparticles.

3. The method of claim 1 wherein the therapeutic comprises one or more hydroxyl groups.

4. The method of claim 1 wherein the therapeutic comprises a taxane.

5. The method of claim 4 wherein the taxane is selected from the group consisting of paclitaxel, docetaxel and mixtures of the same.

6. The method of claim 4 wherein the therapeutic comprises a taxane selected from paclitaxel, polyglutamic acid-paclitaxel, and polyglutamic acid-docetaxel.

7. The method of claim 1 wherein the therapeutic constructs are introduced to the body systemically.

8. The method of claim 7 wherein the therapeutic constructs are administered to the body intravenously.

9. The method of claim 1 wherein the therapeutic constructs are introduced to a tumor in the body via an intra-tumor arterial route.

10. The method of claim 1 further comprising delivering the therapeutic constructs through a membrane adjacent the target cells.

11. The method of claim 10 wherein the membrane comprises a tumor wall.

12. The method of claim 10 wherein the magnetic field generator is controlled to produce a repetitively-varying magnetic field gradient.

13. The method of claim 12 wherein the magnetic field intensity oscillates on and off.

14. The method of claim 12 wherein the magnetic field has an oscillating directional component.

15. The method of claim 14 wherein the oscillating directional component is perpendicular to a direction the therapeutic constructs are to be moved.

16. The method of claim 12 wherein the magnetic field generator comprises an electromagnet, the method further comprising controlling an electrical switch to oscillate power to the electromagnet.

17. The method of claim 12 herein the magnetic field generator comprises two pulsed electromagnets separated by a permanent magnet supplying at least about 50% of the magnetic field directed toward the target cells.

18. The method of claim 17 wherein the two electromagnets are directed parallel to the permanent magnet and wherein the controller is adapted to alternately pulse the electromagnets.

19. The method of claim 17 wherein the two electromagnets are directed at an angle relative to the permanent magnet direction and wherein the controller is adapted to alternately pulse the electromagnets.

20. The method of claim 12 wherein the magnetic field generator comprises three or more oscillating electromagnets surrounding and parallel to a permanent magnet supplying at least about 50% of the magnetic field.

21. The method of claim 1 wherein the therapeutic is bonded to the silane coupling agent through ester linkages, the method further comprising the step of using the controllable magnetic field generator to hold the therapeutic constructs proximate the target cells for at least the time necessary for the ester linkages to be degraded hydrolytically, in vivo and catalyzed by esterases, to release the therapeutic.

22. A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutic construct comprising:

magnetically responsive nanoparticles selected from the group consisting of;

(a) single-domain nanoparticles comprising magnetite and having an average particle size ranging between 1 and 50 nanometers,

(b) clusters of single-domain nanoparticles comprising magnetite, the particles having an average particle size ranging between 1 and 50 nanometers, the clusters having an average cluster size ranging between 5 and 1000 nanometers, and

mixtures of (a) and (b);

a silica coating encapsulating the single-domain nanoparticles;

a first silane coupling agent bonded to the silica coating and having a pendant carboxyl groups capable of selectively binding with a therapeutic;

wherein the first silane coupling agent comprises an alkoxysilylpropyl-O-polyethylene oxide urethane containing monomer units of polyethylene glycol (PEG) terminating in an alcohol function which has been oxidized to a carbox group; and

the therapeutic comprising a taxane selected from the group consisting of paclitaxel, docetaxel and mixtures of the same.

23. The method of claim 22 wherein the cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi'"'"'s sarcoma.